The rule of “the third wheel” may cease to act for a number of purchasing medicines. Health Ministry proposes not to extend it to the procurement of drugs by the decision of medical commissions and the list of trade names. However, if the bidding in the first mechanism occurs everywhere, it is the practice of applying the second does not exist as yet in this list there is no company.The Ministry of health proposes to withdraw the procurement of drugs that can be purchased under trade names, from the application of the rules “the third wheel”. The relevant draft decree of the government Agency posted at the portal regulation.gov.ru. The Ministry also proposes to limit the operation of the principle in the case of purchase of drugs by the decision of the medical Commission for a particular patient.As follows from this document, the Ministry of health has prepared a draft resolution on behalf of the Prime Minister following the meeting on 14 February to discuss the problems of drug provision of patients with cancer. Relevant patient organisations then complained about the disruption of supply by domestic producers and on the quality of their medications (see “Kommersant” on 15 Feb). Enter the gostorg unscrupulous suppliers and manufacturers, in their opinion, contributed to the rule “the third wheel”, which from 2015 prohibits the customers to buy goods from the foreign manufacturer, if the auction there are two domestic. Because procurement of medicines in most cases are allowed to write only the international nonproprietary name procurement of medicines, the use of “the third superfluous” reduced patients ‘ access to foreign drugs.Although the government has established rules of forming the list of drugs that can be purchased under trade names, in 2017, the list of drugs never showed up. Yet to speed up its creation has not helped even the direct instruction of the government of February 14, the Ministry of health to develop it by March 12. As the Director of the Department for interaction with public authorities “Biocad” Alex Trading, the appearance of the list is stopping one of the principles of its formation. “To get on the list to the company—owner of the drug will have to provide clinical evidence that all the drugs inside the INN, except for one, are not working as they should, that is, to conduct research for their comparison. Yet, as we have seen, been wanting to do it was not because of high cost and low probability of obtaining such results,” he says. We note that recently the Ministry of health has released draft amendments to the rules of its formation, however, changes to this requirement are not available (see “Kommersant” on 30 April).”The adoption of the “��ratego extra” has led to the fact that public procurement, and in General the Russian market of steel to leave a quality foreign drugs. Most of the problems appeared in patients with lung cancer, breast cancer, blood. If this rule will cease to operate, once again they will have access to effective treatment,”— says the President of the Association of cancer patients “Hello!” Irina Borovkova. With this change, the Chairman Union “Assistance to patients with cystic fibrosis” Irina Myasnikova, some foreign companies may re-appear the interest in the Russian market, which in turn will solve the problem of the lack of certain medicines in the country.Anastasia Manuylova
